Orchestra BioMed Holdings, Inc.

Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) is a biomedical company focused on cardiovascular disease, developing technologies including its BackBeat cardiac neuromodulation therapy and the Virtue sirolimus-eluting balloon platform. The company filed a Form 10-Q with the SEC on November 5, 2020, accession number 0001213900-20-035161, reflecting its status as a reporting company during that period. Orchestra BioMed operates in the healthcare and medical device sector and ultimately reached the public markets through a special purpose acquisition company structure, with its business centered on addressing hypertension and coronary artery disease through proprietary device-based therapies. For complete filing history, sponsor details, and deal-level analytics on OBIO, sign up for full data access at SpacDesk.